The question was pill versus placebo
OASIS 4 studied 307 adults without diabetes who had obesity, or overweight with a related complication. Participants received oral semaglutide or placebo alongside lifestyle support. At week 64, estimated average weight change was −13.6% and −2.2%, respectively. Gastrointestinal events were reported by 74.0% and 42.2%. This establishes evidence against placebo in that population; it is not a direct comparison with injectable semaglutide, tirzepatide or a compounded oral product.[1]
Why different headlines show different numbers
A treatment-policy analysis asks about the effect of assignment to treatment, including interruptions or discontinuation. An analysis assuming continued treatment answers a different question. Before comparing two percentages, write down the analysis method, population and time point beside each. Otherwise, a difference in how investigators handled treatment use can look like a difference between medicines. The published primary estimate above is a more useful starting point than selecting the largest number from a promotion.[1] For the terminology behind these comparisons, read how to interpret GLP-1 research.
Put the result into a worked example
For arithmetic only, imagine a starting weight of 200 pounds. A 13.6% reduction is 27.2 pounds, while 2.2% is 4.4 pounds. The difference is 22.8 pounds, or 11.4 percentage points of starting weight. Those calculations translate the reported averages; they do not predict a particular person’s result. They also do not mean that everyone lost 27 pounds or that weight change continued at the same pace each month. Dividing the total by 64 weeks would create a misleading weekly target.
Approval and superiority are different claims
Novo Nordisk announced FDA approval of Wegovy tablets in December 2025. In February 2026, FDA challenged advertising that implied the pill offered superior efficacy or safety over other approved GLP-1 treatments. The regulator pointed out that the evidence cited was placebo controlled. For a consumer, that distinction is practical: a preference for avoiding injections can be valid without claiming the pill produces better medical outcomes.[3]
Match the offered product to the evidence
Ask for the full prescription product name and dosage form before paying. Oral Wegovy trial results cannot establish the performance of a different formulation merely because both use the word semaglutide. Then ask the prescriber about the administration routine, other medicines and follow-up. Keep those questions separate from the care membership price. A program’s convenient enrollment process is not evidence that its product is the one studied.[2] Product differences are covered in branded versus compounded GLP-1s.
Why the analysis belongs beside the claim
Consider two otherwise identical comparison cards: one says “average loss among everyone assigned,” while the other says “average loss assuming continued treatment.” A reader planning for possible interruptions may reasonably find the first question more useful. Someone examining biological efficacy may want the second. Neither should be silently substituted for the other. Our approach is to preserve the question being answered, rather than use whichever estimate makes an option look strongest. The distinction is especially important when comparing a trial publication with a sponsor’s promotional summary.
A comparison sheet worth keeping
Use four rows for every option: exact product; relevant study and comparator; practical routine discussed with the clinician; total ongoing cost. Leave unknown fields blank until answered. If an advertisement supplies only a percentage, ask which trial and analysis produced it. If two offers involve different formulations, do not place their trial numbers in one ranked column as though the evidence were interchangeable. The decision is whether a documented option fits your care needs, rather than which headline has the highest percentage.
Put the questions to work
Compare our researched providers or build your provider checklist.
Explore relevant provider reviews
Use these reviews to compare the published services and terms. Inclusion is a research starting point, not a recommendation for treatment.
Continue your research
Sources & scope
Sources checked October 13, 2026. This guide explains published information and consumer research questions; it is not a clinical evaluation.
- OASIS 4 original trial
- Novo Nordisk: Wegovy tablet approval
- FDA: February 2026 Wegovy advertising letter
Prices and terms can change. Confirm your specific offer directly with the provider.